Better than last quarter results for Anthera Pharmaceuticals Inc (NASDAQ:ANTH) - MRK, LLY, IMMU

Northern, WI 03/28/2013 (avauncer) - Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced its financial results on March 27, 2013 for its fourth quarter for the fiscal year ended 2012. It recorded a net loss of $8.9 Million in 4Q2012, which declined a whopping 69.5% compared to the net loss of $29.2 Million in the comparable quarter in the year ago period. Net loss per share was recorded at $0.11 in 4Q2012 compared to $0.71 in the year ago period.

The company also recorded a loss from operation of $8.1 Million in 4Q2012, which plunged 71.3% year over year from being $28.2 Million (loss from operations) in the year ago period.

Total operating expenses declined 71.5% year over year to $8.1 Million compared to the operating expenses of $28.4 Million in the previous year comparable quarter.

After the release of the fourth quarter results, Anthera Pharmaceuticals’ stock price slid to $0.650 in Tuesday’s trading session after opening hitting a high of $0.66. The stock opened at $0.65. Overall, the stock surged a total of 1.56% before closing at $0.65 on March 27, 2013.

Other stocks of related companies, in the biopharmaceutical industry also surged in Tuesday’s trading session with Merck & Co., Inc. (NYSE:MRK) gaining 1.60% to close at $44.39, Eli Lilly & Co (NYSE:LLY) surged 1.205 to end the session at $56.29, and Immunomedics, Inc. (NASDAQ:IMMU) closed at $2.44 before gaining 1.24%.

Anthera Pharmaceuticals is develops and commercializes products which are associated with and are used in the treatment of serious diseases like inflammation, autoimmune diseases, and cardiovascular indications amongst others. It is a biopharmaceutical company.

Price to cash ratio of the company was 0.50. Return on equity and return on investment of Anthera Pharmaceuticals decreased to -300.12% and -175.45%, respectively. However, return on asset remained flat at -113.80%.

The year to date stock performance of ANTH was recorded at 4.84%, The stocks’ annual performance was negative at -73.90%. However, ANTH recorded a positive quarterly and monthly stock performance of 1.56% and 4.84%, respectively.